INBX stock Statistics — Inhibrx Biosciences, Inc. filings, insiders & smart money

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2026-08-07 · filed common shares: 14.71M
Shares float: Sign in
Float %: Sign in
Insider ownership: —
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 22.41%
Short ratioDays to cover, as published by FINRA: 10.39
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 59.10%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 63.30%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross margin: —
Operating margin (nine months)Nine months: 2025-01-01 to 2025-09-30 · Not annualized: -8007.85%
Net margin: —
EBITDA margin (nine months)Nine months: 2025-01-01 to 2025-09-30 · Not annualized: -7860.23%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -1773.60%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -75.44%

Cash & equivalentsas of Jun 26: $133.34M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $181.62M
Debt / equityas of Jun 26: -342.84%
Current ratioas of Jun 26: 5.07
Quick ratio: —
Operating cash flowTTM to Jun 26: -$131.88M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$131.89M
TTM revenue / diluted shareDiluted, TTM to Jun 26: 0.00